We evaluated the combination of locally delivered anti-mesothelin immunotoxins and systemic anti-CTLA-4 in both the 66C14-M murine breast cancer model and the AE17-M murine mesothelioma model. This evidence concerns the gene CTLA4 and breast carcinoma.